International partners to develop immune stimulants for neurology

Brigham and Women's Hospital, immunology company I-Mab Biopharma, neurology company Jiangsu NHWA and CDMO Biodextris partnered to develop intranasally delivered biologics that stimulate the immune system to treat neurological diseases.

Weimin Tang, global business head and EVP of I-Mab Biopharma (Shanghai, China), told BioCentury the project’s origins lay in a Brigham and Women's team observation that cancer patients that received PD-1 or PD-L1 inhibitors experienced improvements in neurological symptoms. For example, cancer patients with Parkinson's disease sometimes see PD symptoms stabilize or improve, he said...